Health Canada Reviewing Link Between Parkinson's Drug Permax And Heart Valve Conditions
"Health Canada is informing Canadians that Permax, a drug used for the treatment of Parkinson's disease, has been withdrawn from the U.S. market amidst concerns about an association with cardiac valvulopathy, a condition involving inflammation or stiffening of the heart valves. "
" Permax (a brand name of the drug pergolide) has been marketed in Canada since 1991 for the treatment of Parkinson's disease. The risk of heart valve problems has been known with this drug and is in the current labelling. Health Canada communicated information regarding this risk to Canadian healthcare providers and patients in 2003 and again in 2004. "
" Two new studies regarding the risk of heart valve problems associated with Permax were published in January 2007. Health Canada is in the process of reviewing these studies and other information to determine what further action will be required regarding Permax. Results of this review will be communicated to the Canadian public and healthcare providers as soon as it is available. Appropriate regulatory action will be taken as necessary. "
" Every drug has benefits and risks associated with its use. In assessing a drug, Health ... read the whole article
comments:(log in to vote on this article or comment on it)